Regulatory phenotype, PD-1 and TLR3 expression in T cells and monocytes from HCV patients undergoing antiviral therapy: A randomized clinical trial

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Su, Shan Shan ^a   He, Huan ^a   Kong, Ling Bo ^a   Zhang, Yu Guo ^a   Zhao, Su Xian ^a   Wang, Rong Qi ^a   Zheng, Huan Wei ^b   Sun, Dian Xing ^c   Nan, Yue Min ^a   Yu, Jun ^d  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b The Fifth Hospital of Shijiazhuang   (China)

^c BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON PLUS RIBAVIRIN; ANTIVIRUS AGENT; CD14 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT ALPHA2B INTERFERON; TOLL LIKE RECEPTOR 3; PDCD1 PROTEIN, HUMAN; TLR3 PROTEIN, HUMAN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD14+ MONOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; OUTCOME ASSESSMENT; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE; BIOSYNTHESIS; BLOOD; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MONOCYTES; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES, REGULATORY; TOLL-LIKE RECEPTOR 3;

EID: 84899430425     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093620     Document Type: Article

References (42)

1. Hadigan C, Kottilil S (2011) Hepatitis C virus infection and co-infection with human immunodeficiency virus: challenges and advancements in management. JAMA 306: 294-301.
2. Munir S, Saleem S, Idrees M, Tariq A, Butt S, et al. (2010) Hepatitis C treatment: current and future perspectives. Virol J 7: 296.
3. Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567. (Pubitemid 41196755)
4. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, et al. (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48: 1843-1850.
5. Shiina M, Rehermann B (2008) Cell culture-produced hepatitis C virus impairs plasma cytoid dendritic cell function. Hepatology 47: 385-395. (Pubitemid 351280706)
6. Zheng Y, Rudensky AY (2007) Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8: 457-462. (Pubitemid 46605910)
7. Speletas M, Argentou N, Germanidis G, Vasiliadis T, Mantzoukis K, et al. (2011) Foxp3 expression in liver correlates with the degree but not the cause of inflammation. Mediators Inflamm 827565: 1-9.
8. Tseng KC, Ho YC, Hsieh YH, Lai NS, Wen ZH, et al. (2012) Elevated frequency and function of regulatory T cells in patients with active chronic hepatitis C. J Gastroenterol 47: 823-833.
9. Sarikonda G, von Herrath MG (2011) Immunosuppressive mechanisms during viral infectious diseases. Methods Mol Biol 677: 431-447.
10. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, et al. (2009) Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 5: e1000313.
11. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, et al. (2008) Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 134: 1927-1937.
12. Urbani S, Amadei B, Tola D, Pedrazzi G, Sacchelli L, et al. (2008) Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol 48: 548-558.
13. Missale G, Pilli M, Zerbini A, Penna A, Ravanetti L, et al. (2012) Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut 61: 1076-1084.
14. + T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
15. Hackl D, Loschko J, Sparwasser T, Reindl W, Krug AB (2011) Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol 41: 1334-1343.
16. Thomas A, Laxton C, Rodman J, Myangar N, Horscroft N, et al. (2007) Investigating Toll-like receptor agonists for potential to treat hepatitis C virus infection. Antimicrob Agents Chemother 51: 2969-2978. (Pubitemid 47206238)
17. Gao YT, Chen RY, Song WQ, Chen CB, Qi ZL, et al. (2004) Prepare and clinical application of HCV genotyping oligochip. Chin J Lab Med 27: 690-693.
18. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB; American Association for Study of Liver Diseases. (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54: 1433-1444.
19. Chung HJ, Lee JW, Kim YS, Lee JI (2013) Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area. Intervirology 56: 178-183.
20. Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, et al. (2010) Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response. J Gastroenterol Hepatol 25: 758-765.
21. Rodriguez-Torres M, Sulkowski MS, Chung RT, Hamzeh FM, Jensen DM (2010) Factors associated with rapid and early virologic response to peginterferon alfa-2a/ribavirin treatment in HCV genotype 1 patients representative of the general chronic hepatitis C population. J Viral Hepat 17: 139-147.
22. Hashad DI, Salem PE, Abdallah DM (2011) Toll like receptor 3 expression as a novel predictor of response to treatment in chronic hepatitis C virus patients. Scand J Clin Lab Invest 71: 641-646.
23. Yuki N, Matsumoto S, Kato M, Yamaguchi T (2010) Hepatic Toll-Like Receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin. J Viral Hepat 17: 130-138.
24. Liao XW, Ling Y, Li XH, Han Y, Zhang SY, et al. (2011) Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 16: 141-147.
25. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW (2002) Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123: 1070-1083.
26. Fitzmaurice K, Klenerman P (2008) Cellular immunity and acute hepatitis C infection. Curr Pharm Des 14: 1666-1677. (Pubitemid 351998591)
27. Bowen DG, Walker CM (2005) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946-952. (Pubitemid 41191670)
28. Frebel H, Richter K, Oxenius A (2010) How chronic viral infections impact on antigen-specific T-cell responses. Eur J Immunol 40: 654-663.
29. Yao S, Wang S, Zhu Y, Luo L, Zhu G, et al. (2009) PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood 113: 5811-5818.
30. + T cells associated with reversible immune dysfunction. J Virol 81: 9249-9258.
31. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, et al. (2008) High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J Immunol 181: 8215-8225.
32. + Treg cells in chronic HCV infected-patients. Virol J 8: 279.
33. Feld JJ, Hoofnagle JH (2005) Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436: 967-972. (Pubitemid 41191673)
34. + T cells is linked to antigen recognition and T cell differentiation. PLoS Pathog 6: e1000947.
35. Seigel B, Bengsch B, Lohmann V, Bartenschlager R, Blum HE, et al. (2013) Factors that determine the antiviral efficacy of HCV-specific CD8(+) T cells ex vivo. Gastroenterology 144: 426-436.
36. + T cells in patients with chronic infection. Gastroenterology 141: 1422-1431.
37. Golden-Mason L, Klarquist J, Wahed AS, Rosen HR (2008) Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 180: 3637-3641.
38. + Th1, Th2, and regulatory T cell clones in hepatitis C. PLoS One 7: e42094.
39. Gay NJ, Gangloff M (2007) Structure and function of Toll receptors and their ligands. Annu Rev Biochem 76: 141-165.
40. Schroder M, Bowie AG (2005) TLR3 in antiviral immunity: key player or bystander? Trends Immunol 26: 462-468. (Pubitemid 41139255)
41. Villacres MC, Literat O, DeGiacomo M, Du W, Frederick T, et al. (2008) Defective response to Toll-like receptor 3 and 4 ligands by activated monocytes in chronic hepatitis C virus infection. J Viral Hepat 15: 137-144.
42. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 105: 7034-7039. (Pubitemid 351754525)